According to a recent LinkedIn post from Neuromod Devices Ltd, Canadian TV outlet CTV News featured a segment on chronic tinnitus and Neuromod’s Lenire device. The post cites an interview with a Toronto-based professional who described a significant reduction in tinnitus symptoms after using Lenire, framed against survey data indicating high tinnitus prevalence in Canada.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights that Lenire is now available through 21 clinics across Alberta, British Columbia, Manitoba, Ontario, and Québec, with further expansion in Canada expected in 2026. For investors, the post suggests that Neuromod is in an early commercialization phase in a large, underserved market, which could support future revenue growth if clinical adoption broadens and reimbursement pathways develop.
The post also notes that CTV News interviewed Neuromod’s CEO, Dr. Ross O’Neill, and a clinician from Sunnybrook regarding tinnitus causes and treatment. Such media exposure may enhance brand awareness and clinician engagement, potentially strengthening Neuromod’s competitive position in the tinnitus treatment space, though the post does not provide any financial metrics, pricing details, or specific revenue targets.